# Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

> **NCT06848946** · PHASE4 · RECRUITING · sponsor: **Glaukos Corporation** · enrollment: 132 (estimated)

## Conditions studied

- Glaucoma, Open-angle
- Ocular Hypertension (OHT)
- Phacoemulsification Cataract Surgery

## Interventions

- **COMBINATION_PRODUCT:** iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery
- **PROCEDURE:** Sham procedure in conjunction with cataract surgery

## Key facts

- **NCT ID:** NCT06848946
- **Lead sponsor:** Glaukos Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-13
- **Primary completion:** 2026-08
- **Final completion:** 2027-06
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06848946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06848946, "Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06848946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*